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Summary.-(1) The antigenic activity of basic protein extracts of a variety of human
tissues towards sensitized lymphocytes from cancer patients has been studied using
the macrophage electrophoretic migration method.
(2) Basic protein prepared from human tumour tissue has antigenic properties
which differ from basic protein prepared from normal tissues, from hyperplastic
tissue and even tumour bearing host tissue.
(3) Tumour type antigenic molecules are at least 104 times less numerous on
normal cells than on tumour cells. If our reasoning is accepted then they are absent
from normal cells, and thus restricted in vivo to malignant cells.
(4) Hyperplastic tissues (gynaecomastia, etc.) do not contain cancer basic protein.
(5) Human chronic lymphatic leukaemic leucocytes possess the same type of cancer
antigenic activity as solid tumours. This antigenic activity is not shared by normal
lymphocytes.
MANY tumour-produced antigens have
been described, each of which appears to
be characteristic only of a particular
tumour or tumour type (see for example
Baldwin and Glaves, 1972). We can find
no published evidence, other than our
own, that tumours may have a common
but specific antigen, though quite recently
it has been reported (Taranger et al.,
1972) that different tumour types from
the same organ may share cell sensitizing
antigens.
Hashim and Eylar (1969) from their
detailed study ofthe immunogenic proper-
ties of the tryptophan peptide of the
basic protein of myelin (encephalitogenic
factor, EF) concluded that it provoked
predominantly cellular sensitization and
gave rise to little, if any, circulating anti-
body. Because of the general similarity
between EF and the basic protein extract-
able from tumours (Caspary and Field,
1971), the latter might be expected to
show a similar propensity to produce cell
bound rather than humorally mediated
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reactions. Klein (I 967) has emphasized
the importance, in tumour immunology,
of cell operated reactions as opposed to
those dependent on free antibody. Study
of cellular sensitization in man has been
much hampered by the lack of a simple,
reproducible and quantitative method of
assessment (Bloom, 1971). The intro-
duction of the macrophage electrophoretic
migration (MEM) method (Field and
Caspary, 1970) enabled some properties
of the antigen(s) of human tumours to be
established. Later (Caspary and Field,
1971) evidence was brought forward that
there might be one antigen common to
all human tumours. Whilst lymphocyte
sensitization to EF in human malignant
disease has now been independently con-
firmed (Pritchard et al., 1972) the relation-
ship between cancer basic proteins of
different provenance remains to be clari-
fied. The present work explores and
compares the properties of basic protein
extracted from a number of tumours with
that derived from the surrounding normalJ. P. DICKINSON, E. A. CASPARY AND E. J. FIELD
(host) tissues. It also examines the rela-
tion of these proteins to those obtainable
from a few other hyperplastic tissues. It
becomes clear that special antigenic acti-
vity is present in all malignant tissues
examined including leukaemic white cells,
but not in host tissue. Also this antigen
from tumours is qualitatively different
from tlhat derived from normal tissue,
though the lymphocytes of cancer patients
respond to both.
MATERIALS AND METHODS
Lymphocytes were prepared from 10-15
ml ofvenous blood, from patients with malig-
nant neoplasia, by the method ofCoulson and
Chalmers (1964) as modified by Hughes and
Caspary (1970). This involves sedimentation
of erythrocytes and polymorphs in methyl
cellulose and saccharated iron solution, and
gives a preparation containing a high propor-
tion (>95%o) of lymphocytes of greater than
9500 viability (as estimated by dye exclu-
sion). Normal guinea-pig macrophages were
prepared by injecting sterile liquid paraffin
intraperitoneally and washing out at 5-10
days with heparinized Hanks' solution.
Preparation of tuanour antigens
Tumour specimens were collected from
the operating table, sampled for histology,
rinsed free of blood, etc., and then dissected
into macroscopic tumour and normal looking
tissues. Other tissues were obtained from
early post-mortem examinations. Each was
minced with scissors and either processed
immediately or stored at -70°C.
Tumourtissue and surrounding apparently
normal tissue was obtained from two cancers
of the stomach, two of the colon, one of the
breast and one of the bronchus. Two speci-
mens of benign gynaecomastic breast were
also studied, as wAell as a thyroid specimen
from Hashimoto's thyroiditis and a (non-
malignant) spleen removed with one of the
stomach carcinomata. Normal erythrocytes
were obtained through the Regional Blood
Transfusion Centre; normal leucocytes from
laboratory workers; and leukaemic lympho-
cytes with the cooperation ofDr R. L. Powles
of the Chester Beatty Research Institute
and Dr C. B. Freeman of the Haematology
Unit of the Manchester Royal Infirmary.
Antigens w%ere prepared from these tissues
as described below (Caspary, and Field 1971;
Carnegie, Caspary and Field, 1972).
Step (i) Homogenization. The chopped
tissue was homogenized in a WVaring blendor
(all operations at 0°-4°C) with 4 vols of
water and centrifuged at 23,000 g max for
30 min. Rehomogenization aind recentri-
fugation of the pellets first in physiological
saline and then in water were carried out
before freeze drying of the reImaining pellets.
Step (ii) Defatting. The frozen dried
tissues wNere defatted by homogenization in
10 vols of chloroform: methanol (2: 1, v: v)
and filtration under suction. After airdrying
the residues may be stored or acid extracted.
Step (iii) Acid extraction. The dry,
defatted tissues were dispersed in 5 vols 500
saline and centrifuged at 23,000 g for 30 min.
The supernatant wras discarded and the
pellets suspended in 5 vols wvater. The
suspension was adjusted to, and maintained
at, pH 3 5 for 30 min, recentrifuged as
before, and the supernatant discarded. The
pellets were suspended in 5 vols Awater and
the suspension adjusted to, and maintained
at, pH 2-6 for a period 3-18 hours, then
recentrifuged as before. The pellets were
w^rashed at pH 2-6, and the combined pH 2 6
supernatants dialysed and freeze dried. This
freeze dried extract represents the crude,
water soluble antigen.
Fresh (ca. 8 hours post-mortem) disease
free liver and kidney were taken through
steps (i) and (iii) only of the extraction
procedure, since Adams (1972) has shown
that a variable fraction of normal tissue
antigen (equated with at least part of Adams'
acid extractable membrane protein) may be
extracted into chloroform: methanol-2 :1.
Extractsfromdispersed cells. Erythrocyte
stromata wN-ere prepared by the method of
Tashian (1962). Washed cells or stromata
were suspended in water and the suspension
adjusted to, and maintained at, pH 2-6 for
2-5 hours. After centrifugation the super-
natant was dialysed against water and freeze
dried.
Macrophage electrophoretic migrationt (MEM)
method
In principle the test depends upon the
interaction of antigen wiith specifically sensi-
tized lymphocytes to liberate a protein
(Caspary, 1971, 1972) which has the property
of causing normal guinea-pig mnacroplhages
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to travel more slowly in an electric field. In
practice, 0.5 x 106 lymphocytes from a
cancer patient were mixed with 107 irradiated
normal guinea-pig peritoneal macrophages
and the antigen to be tested. After incuba-
tion at 20°C for 90 min, the time ofmigration
of macrophages (readily recognized under
phase contrast illumination by their liquid
paraffin content and size) was measured in a
Zeiss cytopherometer. (Irradiationofmacro-
phage exudate was carried out in order to
obviate-at least temporarily-a mixed
lymphocyte reaction between the human and
guinea-pig cells.) Ten cells were timed in
both directions of the potential difference
so that a mean of 20 readings could be
established. If tc = time when no antigen
is present (i.e. human lymphocytes plus
irradiated macrophages incubated alone),
and te = time when antigen is also present,
then ingeneral te > tc and (te-tc)(tc) X 100
represents the percentage increase in migra-
tion time and is a measure ofthe lymphocyte
sensitization. A comprehensive account of
the technique together with a specimen
protocol in extenso is given by Caspary and
Field (1971).
Throughout this work, an extract of one
particular carcinoma of cervix (1CC) was
used as a reference antigen-i.e. all activities
measured were referred back to that of this
standard.
RESULTS
The reference antigen (1CC) with the
lymphocytes from the 7 patients with
cancer used in this study gave slowings
between 14-0-16-7% (mean 15-2 i 0-8%),
but with lymphocytes from normal indivi-
duals gave slowings always less than 3%.
The 14-0-16-7% slowings are hereafter
taken as 100, and experimental values,
expressed proportionally, are termed
" relative slowings ".
(i) Basic protein from tumour as com-
pared with surrounding non-malignant
(host) tissue.-The relative slowings given
by tumour basic protein and host tissue
basic protein are compared in Table I.
It can be seen in each case that the
activity ofthe material obtained from the
tumour is equal to that of 1CC, and in
every case that of the host tissue is
significantly less-about two-thirds that
of the tumour protein. Experience has
shown that with the standardized experi-
mental conditions differences in relative
slowing of greater than 15.0% correspond
with P <0 01. The yields ofbasic protein
extracted from each tissue, and also given
in Table I, were remarkably similar.
(ii) Normal compared with hypertrophic
non-malignant tissue.-Table II presents
corresponding data obtained with the
basic protein extracts from normal and
hyperplastic tissues. It is apparent that
the results obtained with carcinoma cervix
(1CC) and leukaemic lymphocyte basic
TABLE I.-Comparison of Yields of, and Macrophage Slowings Produced by, Acid
Extracts ofTumours and Surrounding Host Tissues
Specimen
Carcinoma colon 1
Carcinoma colon 2
Carcinoma stomach 1
Carcinoma stomach 2
Carcinoma bronchus
Carcinoma breast
MEAN + S.D.
Carcinomatous tissue
A
Yield ofacid
extract. mg/g Relative macro-
wet weight phage slowing*
2-8 97
1-7 95
1-1 96
1-3 93
1-1 99
5-8 100
2-3 97 ± 3
Host tissue
Yield ofacid
extract. mg/g Relative macro-
wet weight phage slowing*
5 0 64
2-7 69
0-8 61
1-9 71
1.5 62
1-4 60
2-2 65±5
* Experimental macrophage slowings are expressed proportionally to the slowing (=100) produced by
an extract of a carcinoma cervix uteri (1CC-used throughout as a reference antigen) interacting on the
same cancer lymphocytes as used for the particular measurement recorded. Extracts were tested at
100 ,ug/test. Extracts tested against macrophages alone (i.e. lymphocytes) produced insignificant slowings
( <1 5%). The actual slowing produced by 1CC was 15 - 2% ± 0
- 8 (mean of 7 determinations at different
times and with lymphocytes from different cancer patients).
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TABLE II.-CoMparison of Yieldsof, and MacrophageSlowing Produced by, AcidExtracts
of Various Tumours, Normal Tissues and Hyperplastic Tissues
Specimen
Tumours
Carcinoma cervix uteri
Leukaemic lymphocytes
Normal ti88Ue8
Liver 1
Liver 2*
Kidney*
Breast-Acinar tissue
Breast-Fatty tissue
Erythrocytes*
Lymphocytes*, t
Hyperplastic tissues
Spleent
" Hashimoto " thyroid
Chronic mastitis
Gynaecomastia 1
Gynaecomastia 2
Yield of acid extract
-mg/g or mg/109 cells
5.9
10-0
3 4
1-1
3 0
0-1
0-2
0-1
31-0
0 6
0 9
0*5
1.0
0*5
Relative macrophage
slowing
100
95
71
62
65
63
62
53
64
67
67
65
65
69
* Extraction conducted without chloroform: methanol defatting.
t Spleen (144 g) taken from patient yielding carcinoma stomach 2 (Table I).
I Contaminated with erythrocytes; acid extract includes haemoglobin.
proteins stand apart from those with
normal or hypertrophic tissues. These
latter, moreover, behave in the same
manner as hypertrophic, non-host tissue
from a cancer patient.
The whole group of non-cancer basic
proteins, comprising normal tissue, hyper-
trophic tissue and host tissue, fall within
the range 53-71 (mean 64 ± 4, n 17)
as compared with the overall cancer basic
protein range of 93-100 (mean 97 ± 3,
n =8).
(iii) Absence of tumour antigen from
normal tissue.-Whilst it is clear that the
basic protein from cancer tissue behaves
differently from that of normal tissue an
attempt was made to find out whether
cancer antigen might be present in very
small amounts in normal tissue. To do
this, extracts from leukaemic and from
normal lymphocytes were tested as anti-
gens in amounts corresponding with 106
and 103 leukaemia cells and 106 and 107
normal lymphocytes i.e. the amount of
material obtained from 107 normal cells
was tested for activity as compared with
that obtainable from 103 leukaemia cells.
Table III shows that whilst the equivalent
of 103 leukaemic cells elicited full response
from cancer lymphocytes, even 107 normal
lymphocytes gave no more than the
customary " normal tissue " response. It
is concluded that, cell for cell, there must
be at least 104 times less cancer antigen
present on the normal lymphocyte than is
present on a leukaemic cell.
In a further enquiry into the presence
of even traces of cancer antigen in normal
tissue, basic protein from tumour and
host tissue sources was tested at concen-
trations of 0 1 pg and 1P0 mg (1000 ,ug)
respectively. The results in Table III
show that both in the case of colon and
stomach, 01 ,ug of tumour tissue protein
gave a full reaction with cancer lympho-
cytes whilst 1 mg (i.e. 10,000 times as
much) normal tissue extract still only gave
the reaction associated with normaltissue.
Finally, in order to eliminate the
possibility of some unexpected inter-
ference between tumour and normal
tissue extracts it was shown (Table III)
that 01 jtg of tumour protein mixed with
1000 ,ug of host tissue protein still gave
the activity characteristic of tumour
protein.
(iv) Leukaemic leucocytes.-It is
apparent that chroniclymphatic leukaemic
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TABLE III. Effect of Variation of -Dose, and of Mixiny of Acid Extracts
Source
Meteriel teste(I
Tumour extract
Ttumouir extract +
host, or normal
tisstue extract
Carcinoma coloin 1
Relative
Dose-jug slowing
100
0*1I
01
1000
97
104
101
Carcinioma stomach I
Relative
Dose-tjg slo-wing
100
0.1
0.1
1000
96
103
100
Leukaemia*
Dose-
no. of Relative
cells slowing
106
103
103
+
107
95
104
100
Host or normal 100 64
tisstue extract 1000 66
* Whilst leuikaemic lymphocytes are themselves
cancer basic protein or in(ieed several other antigenis
themselves well ondowedl with cancer anitigen.
cells are ain effective source of cancer
antigen with the same qualitative proper-
ties as that obtained from solid tumours.
This finding must be clearly distinguished
from the inability of leukaemic lympho-
cytes themselves to react with various
antigens (EF, cancer antigen) as reported
by Field and Caspary (1970). This
tumour type antigenic activity may form
the basis for the recorded antigenicity of
autogenous leukaemic leucocytes towards
the lymphocytes of leukaemic patients
in remission (Powles et al., 1971).
Leukaemic cells may be used as a simple
stock of particulate cancer antigen for
routine testing (Field and Caspary-
unpublished results).
DISCUSSION
In order to validate the conclusion
that tumour tissue contains antigen quali-
tatively different from that in normal
tissue it is necessary to be sure that the
differences established are not the result
of inadequacies of the test system. Tn
very advanced cases of cancer, lympho-
cyte sensitization, as judged by the
standardized test using 0 5 x 106 lympho-
cytes, appears reduced, but more typical
responses may be obtained with increased
cell numbers (e.g. 5 X 106): this suggested
some reduiction in the number of sen-
sitized cells in these cases. Basic work
(Carnegie, Caspary, Dickinson and Field,
1973) has shown that above a critical
number of lymphocytes per test,
100 61 106 64
100( 60 . 10 71
unable to respond to encephalitogenic factor (EF),
(inclui(inlg PPD) (Field and Caspary, 1970) they are
and with a sufficiency of antigen, a
maximal, plateau, macrophage slowing
is obtained. In particular it was shown
that, with various TP's and NP's and
lymphocytes from ordinary cancer
patients, 01 x 106 lymphocytes were
sufficient to give the maximal response.
In the present work 0-5 x 106 lympho-
cytes have been used routinely. The
potential for development of maximal
response has been demonstrated with
each set of lymphocytes by testing with a
reference tumour extract (ICC), when
slowings between 14-0-16 7% were
obtained. This compares well with the
mean slowing of 1580% (S.D. 170%;
n 73) obtained with lymphocytes from
44 cancer patients tested seriatim over the
last 6 months with 1CC. Lymphocytes
from normal persons gave insignificant
macrophage slowings with ICC (i.e. <30 ).
Additionally, pairs of extracts from
tumours and their respective host tissues
were tested on aliquots of the same set of
lymphocytes. In these cases the lower
macrophage slowing with host tissue
extract cannot have been a result of an
insufficiency of lymphocytes sensitized to
the tumour type antigen.
A sufficient dose of tumour basic
protein extract has been used in the tests
since (i) maximal responses i.e. relative
macrophage slowings 97 ± 3 0 (n 7)
were obtained, and (ii) in three instances
the same (maximal) slowings were
obtained when one thousandth of the
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usual quantity of tumour basic protein
was used as antigen (Table III). That
sufficient host or normal tissue basic
protein was used was shown in three
instances by retesting materials at higher
doses (Table III). For instance the host
colon tissue extract from the case carci-
noma colon 1 gave relative macrophage
slowings of 64% when tested at 10O,tg
and 66% when tested at 1000 ,ug/test.
The mean of the maximal relative
macrophage slowings given by all normal,
cancer host, and hyperplastic tissues was
64 ± 4 (n = 17) ofthe maximum response
given by the cancer basic proteins. This
is interpreted as meaning that there is a
qualitative difference in the antigenic
properties of cancer when compared with
normal tissue (either host, from normal
individuals, orin ahyperplastic condition).
Moreover, the similarity of activity of
extracts derived from different neoplasms
reported by Caspary and Field (1971)
and Caspary (1972) is again demonstrated.
It should perhaps be made clear that
the previously used muscle antigen to
which the lymphocytes of cancer patients
show no speei&l reactivity (Field and Cas-
pary, 1972) w'as a simple aqueous extract
of normal muscle: acid extracts ofnormal
muscle show normal tissue type antigeni-
city.
The results presented in Table III
show that, on a weight basis, tumour
tissue-since the yields of extracts from
tumour and normal tissue are very similar
-must contain at least 104 times more of
the tumour type antigenicity as does
normal tissue. Moreover, admixture of
one portion of tumour protein in ten
thousand of normal tissue protein is
sufficient to give a full cancer result
(Table III). It has been established
that the special antigenic activity resides
on the cancer cell surface, and not in
endoplasmic reticulum, cell sap, mito-
chondria or nucleus (Dickinson, Caspary
and Field, 1972). It has indeed been
possible to calculate that each tumour cell
carries about 104 molecules of antigenic-
ally active material. It would follow
that normal cells carry no antigenic
molecules with tumour type activity and
conversely that tumour type activity is
indeed restricted to tumour cells in vivo.
Our results, however, do not exclude the
possibility that such antigenic determi-
nants may lie latent in normal cells and
be revealed by subtle, and even simple,
rearrangements or alterations of pre-
existing molecular groupings.
Several cell-sensitizing antigens present
in the plasma membrane of tumour cells
have been described previously, but these
appear to be either type specific or tissue
specific (Baldwin and Glaves, 1972;
Taranger et al., 1972; Bubenik et al.,
1970; Chu et al., 1967).
Even were these type or tissue specific
antigens to preserve their antigenic proper-
ties through our extraction procedure,
it is unlikely for two reasons that they
would be detected in our assay system.
Firstly, the lymphocyte donors have had
tumours quite differently sited and histo-
logically different from those serving as
sources of antigen; secondly, the effect
ofthe common tumour antigen (indirectly)
on the macrophages seems to be maximal
(Carnegie et al., 1973) and response to
further antigens would produce no extra
slowing. The results obtained by Bjork-
lund over several years (see inter alia
Bjorklund and Bjorklund, 1957; Bjork-
lund, 1961, 1968) which have very recently
come to our notice, suggest that other
methods of detection of a common
antigen are practicable, though failure
to detect such an antigen has led to the
current belief that it cannot exist.
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